ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
10.76
-0.22 (-2.00%)
At close: Jan 29, 2026, 4:00 PM EST
10.76
0.00 (0.00%)
After-hours: Jan 29, 2026, 6:20 PM EST
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 106 employees as of September 30, 2025. The number of employees decreased by 6 or -5.36% compared to the same quarter last year.
Employees
106
Change
-6
Growth
-5.36%
Revenue / Employee
n/a
Profits / Employee
-$1,276,132
Market Cap
1.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 106 | -6 | -5.36% |
| Jun 30, 2025 | 128 | 21 | 19.63% |
| Mar 31, 2025 | 122 | 20 | 19.61% |
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Sep 30, 2024 | 112 | 19 | 20.43% |
| Jun 30, 2024 | 107 | 18 | 20.22% |
| Mar 31, 2024 | 102 | 14 | 15.91% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Sep 30, 2023 | 93 | 5 | 5.68% |
| Jun 30, 2023 | 89 | 6 | 7.23% |
| Mar 31, 2023 | 88 | 9 | 11.39% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Sep 30, 2022 | 88 | 14 | 18.92% |
| Jun 30, 2022 | 83 | 13 | 18.57% |
| Mar 31, 2022 | 79 | 13 | 19.70% |
| Dec 31, 2021 | 78 | 17 | 27.87% |
| Sep 30, 2021 | 74 | 14 | 23.33% |
| Jun 30, 2021 | 70 | 12 | 20.69% |
| Mar 31, 2021 | 66 | 9 | 15.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Phathom Pharmaceuticals | 427 |
| Vir Biotechnology | 408 |
| Capricor Therapeutics | 160 |
| Nanobiotix | 103 |
| MoonLake Immunotherapeutics | 100 |
| Compass Therapeutics | 35 |
ORIC News
- 9 days ago - ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside - Seeking Alpha
- 16 days ago - ORIC Pharmaceuticals, Inc. (ORIC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones - GlobeNewsWire
- 23 days ago - ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Results and Differentiation in EGFR-Mutated Non-Small Cell Lung Cancer Transcript - Seeking Alpha
- 7 weeks ago - ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - GlobeNewsWire
- 7 weeks ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 - GlobeNewsWire